devices, and highly dynamic price variation are only few examples.
Perhaps the reader may want to think of whether she wishes to address the "normative" or the "positive" nature of the question (normative statements are concerned with describing how things should or ought to be, how to value them, which things are good or bad, which actions are right or wrong. Positive statements on the other hand are descriptive or explanatory, and in that sense are falsifiable statements that attempt to describe reality). That is, one could attempt to describe the status quo relating to the economic evaluation of drugs and medical devices. Alternatively, one could ask whether economic evaluation of drugs and devices should be different.
Inevitably, these questions will lead to others-such as: Should the decision-making requirements for coverage and reimbursement be different for drugs and medical devices? Should the regulatory framework be the same?
These are important issues that researchers, policymakers, and the pharmaceutical and medical devices industry may need to address in the future.
We hope this debate will stimulate readers to express their views on the question at hand with their colleagues, sharing their experiences in the field.
